{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:04:07Z","timestamp":1791313447395,"version":"4.3.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The bacterial pathway for fatty acid biosynthesis, FASII, is a target for development of new anti-staphylococcal drugs. This strategy is based on previous reports indicating that self-synthesized fatty acids appear to be indispensable for\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    growth and virulence, although other bacteria can use exogenous fatty acids to compensate FASII inhibition. Here we report that staphylococci can become resistant to the FASII-targeted inhibitor triclosan\n                    <jats:italic>via<\/jats:italic>\n                    high frequency mutations in\n                    <jats:italic>fabD<\/jats:italic>\n                    , one of the FASII genes. The\n                    <jats:italic>fabD<\/jats:italic>\n                    mutants can be conditional for FASII and not require exogenous fatty acids for normal growth, and can use diverse fatty acid combinations (including host fatty acids) when FASII is blocked. These mutants show cross-resistance to inhibitors of other FASII enzymes and are infectious in mice. Clinical isolates bearing\n                    <jats:italic>fabD<\/jats:italic>\n                    polymorphisms also bypass FASII inhibition. We propose that fatty acid-rich environments within the host, in the presence of FASII inhibitors, might favour the emergence of staphylococcal strains displaying resistance to multiple FASII inhibitors.\n                  <\/jats:p>","DOI":"10.1038\/ncomms12944","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T06:10:15Z","timestamp":1475647815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8435-0523","authenticated-orcid":false,"given":"Claire","family":"Morvan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"K\u00e9nanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Anba-Mondoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Brinster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Trieu-Cuot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Poyart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lamberet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Gloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7426-5229","authenticated-orcid":false,"given":"Alexandra","family":"Gruss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"key":"BFncomms12944_CR1","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1001\/jamainternmed.2013.8277","volume":"173","author":"FD Lowy","year":"2013","unstructured":"Lowy, F. D. Methicillin-resistant Staphylococcus aureus: where is it coming from and where is it going? JAMA Internal Med. 173, 1978\u20131979 (2013).","journal-title":"JAMA Internal Med."},{"key":"BFncomms12944_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.meegid.2013.04.030","volume":"21","author":"AC Uhlemann","year":"2014","unstructured":"Uhlemann, A. C., Otto, M., Lowy, F. D. & DeLeo, F. R. Evolution of community- and healthcare-associated methicillin-resistant Staphylococcus aureus. Infect. Genet. Evol. 21, 563\u2013574 (2014).","journal-title":"Infect. Genet. Evol."},{"key":"BFncomms12944_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1179\/1973947812Y.0000000061","volume":"25","author":"MA Banevicius","year":"2013","unstructured":"Banevicius, M. A., Kaplan, N., Hafkin, B. & Nicolau, D. P. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J. Chemother. 25, 26\u201331 (2013).","journal-title":"J. Chemother."},{"key":"BFncomms12944_CR4","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1128\/AAC.01248-10","volume":"55","author":"S Escaich","year":"2011","unstructured":"Escaich, S. et al. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob. Agents Chemother. 55, 4692\u20134697 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFncomms12944_CR5","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1021\/ja207662w","volume":"134","author":"Z Feng","year":"2012","unstructured":"Feng, Z., Chakraborty, D., Dewell, S. B., Reddy, B. V. & Brady, S. F. Environmental DNA-encoded antibiotics fasamycins A and B inhibit FabF in type II fatty acid biosynthesis. J. Am. Chem. Soc. 134, 2981\u20132987 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"BFncomms12944_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.coph.2012.07.004","volume":"12","author":"DT Moir","year":"2012","unstructured":"Moir, D. T., Opperman, T. J., Butler, M. M. & Bowlin, T. L. New classes of antibiotics. Curr. Opin. Pharmacol. 12, 535\u2013544 (2012).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFncomms12944_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jac\/dkm236","volume":"60","author":"HS Park","year":"2007","unstructured":"Park, H. S. et al. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J. Antimicrob. Chemother. 60, 568\u2013574 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFncomms12944_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ijantimicag.2007.07.006","volume":"30","author":"HS Park","year":"2007","unstructured":"Park, H. S. et al. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. Int. J. Antimicrob. Agents 30, 446\u2013451 (2007).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFncomms12944_CR9","doi-asserted-by":"publisher","first-page":"15987","DOI":"10.1074\/jbc.M113.532804","volume":"289","author":"J Schiebel","year":"2014","unstructured":"Schiebel, J. et al. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor. J. Biol. Chem. 289, 15987\u201316005 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFncomms12944_CR10","doi-asserted-by":"publisher","first-page":"7612","DOI":"10.1073\/pnas.0700746104","volume":"104","author":"J Wang","year":"2007","unstructured":"Wang, J. et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl Acad. Sci. USA 104, 7612\u20137616 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms12944_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04784","volume":"441","author":"J Wang","year":"2006","unstructured":"Wang, J. et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441, 358\u2013361 (2006).","journal-title":"Nature"},{"key":"BFncomms12944_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/28970","volume":"394","author":"LM McMurry","year":"1998","unstructured":"McMurry, L. M., Oethinger, M. & Levy, S. B. Triclosan targets lipid synthesis. Nature 394, 531\u2013532 (1998).","journal-title":"Nature"},{"key":"BFncomms12944_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1440-1754.1994.tb00568.x","volume":"30","author":"J Webster","year":"1994","unstructured":"Webster, J., Faoagali, J. L. & Cartwright, D. Elimination of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit after hand washing with triclosan. J. Paediatr. Child Health 30, 59\u201364 (1994).","journal-title":"J. Paediatr. Child Health"},{"key":"BFncomms12944_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0195-6701(99)90047-6","volume":"41","author":"AI Bamber","year":"1999","unstructured":"Bamber, A. I. & Neal, T. J. An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J. Hosp. Infect. 41, 107\u2013109 (1999).","journal-title":"J. Hosp. Infect."},{"key":"BFncomms12944_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0196-6553(96)90017-6","volume":"24","author":"HN Bhargava","year":"1996","unstructured":"Bhargava, H. N. & Leonard, P. A. Triclosan: applications and safety. Am. J. Infect. Control 24, 209\u2013218 (1996).","journal-title":"Am. J. Infect. Control"},{"key":"BFncomms12944_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0195-6701(03)00222-6","volume":"55","author":"NP Brenwald","year":"2003","unstructured":"Brenwald, N. P. & Fraise, A. P. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). J. Hosp. Infect. 55, 141\u2013144 (2003).","journal-title":"J. Hosp. Infect."},{"key":"BFncomms12944_CR17","doi-asserted-by":"publisher","first-page":"14158","DOI":"10.1073\/pnas.1211314109","volume":"109","author":"G Cherednichenko","year":"2012","unstructured":"Cherednichenko, G. et al. Triclosan impairs excitation-contraction coupling and Ca2+ dynamics in striated muscle. Proc. Natl Acad. Sci. USA 109, 14158\u201314163 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms12944_CR18","doi-asserted-by":"publisher","first-page":"e01015","DOI":"10.1128\/mBio.01015-13","volume":"5","author":"AK Syed","year":"2014","unstructured":"Syed, A. K., Ghosh, S., Love, N. G. & Boles, B. R. Triclosan promotes Staphylococcus aureus nasal colonization. MBio 5, e01015 (2014).","journal-title":"MBio"},{"key":"BFncomms12944_CR19","doi-asserted-by":"crossref","unstructured":"Yueh, M. F. et al. The commonly used antimicrobial additive triclosan is a liver tumor promoter. Proc. Natl Acad. Sci. USA (2014).","DOI":"10.1073\/pnas.1419119111"},{"key":"BFncomms12944_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijantimicag.2012.04.021","volume":"40","author":"ML Ciusa","year":"2012","unstructured":"Ciusa, M. L. et al. A novel resistance mechanism to triclosan that suggests horizontal gene transfer and demonstrates a potential selective pressure for reduced biocide susceptibility in clinical strains of Staphylococcus aureus. Int. J. Antimicrob. Agents 40, 210\u2013220 (2012).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFncomms12944_CR21","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1038\/nature08667","volume":"463","author":"W Balemans","year":"2010","unstructured":"Balemans, W. et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature 463, E3\u2013E4 (2010).","journal-title":"Nature"},{"key":"BFncomms12944_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ejps.2013.08.019","volume":"50","author":"N Kaplan","year":"2013","unstructured":"Kaplan, N., Garner, C. & Hafkin, B. AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. Eur. J. Pharm. Sci. 50, 440\u2013446 (2013).","journal-title":"Eur. J. Pharm. Sci."},{"key":"BFncomms12944_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.mib.2011.07.029","volume":"14","author":"JB Parsons","year":"2011","unstructured":"Parsons, J. B. & Rock, C. O. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr. Opin. Microbiol. 14, 544\u2013549 (2011).","journal-title":"Curr. Opin. Microbiol."},{"key":"BFncomms12944_CR24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.str.2012.03.013","volume":"20","author":"J Schiebel","year":"2012","unstructured":"Schiebel, J. et al. Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality. Structure 20, 802\u2013813 (2012).","journal-title":"Structure"},{"key":"BFncomms12944_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nature07772","volume":"458","author":"S Brinster","year":"2009","unstructured":"Brinster, S. et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458, 83\u201386 (2009).","journal-title":"Nature"},{"key":"BFncomms12944_CR26","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1038\/nature08668","volume":"463","author":"S Brinster","year":"2010","unstructured":"Brinster, S. et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature 463, E4\u2013E5 (2010).","journal-title":"Nature"},{"key":"BFncomms12944_CR27","doi-asserted-by":"publisher","first-page":"15378","DOI":"10.1073\/pnas.1109208108","volume":"108","author":"JB Parsons","year":"2011","unstructured":"Parsons, J. B., Frank, M. W., Subramanian, C., Saenkham, P. & Rock, C. O. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc. Natl. Acad. Sci. USA 108, 15378\u201315383 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFncomms12944_CR28","doi-asserted-by":"publisher","first-page":"e00613","DOI":"10.1128\/mBio.00613-13","volume":"4","author":"L Zhu","year":"2013","unstructured":"Zhu, L. et al. The two functional enoyl-acyl carrier protein reductases of Enterococcus faecalis do not mediate triclosan resistance. MBio 4, e00613\u2013e00613 (2013).","journal-title":"MBio"},{"key":"BFncomms12944_CR29","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1128\/AAC.01411-12","volume":"56","author":"N Kaplan","year":"2012","unstructured":"Kaplan, N. et al. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob. Agents Chemother. 56, 5865\u20135874 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFncomms12944_CR30","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1128\/AAC.02307-12","volume":"57","author":"JB Parsons","year":"2013","unstructured":"Parsons, J. B. et al. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob. Agents Chemother. 57, 2182\u20132190 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFncomms12944_CR31","doi-asserted-by":"publisher","first-page":"10532","DOI":"10.1073\/pnas.1408797111","volume":"111","author":"JB Parsons","year":"2014","unstructured":"Parsons, J. B. et al. Identification of a two-component fatty acid kinase responsible for host fatty acid incorporation by Staphylococcus aureus. Proc. Natl Acad. Sci. USA 111, 10532\u201310537 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms12944_CR32","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1128\/AAC.01038-13","volume":"57","author":"JB Parsons","year":"2013","unstructured":"Parsons, J. B., Frank, M. W., Rosch, J. W. & Rock, C. O. Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice. Antimicrob. Agents Chemother. 57, 5729\u20135732 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFncomms12944_CR33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00280009","volume":"232","author":"J Coleman","year":"1992","unstructured":"Coleman, J. Characterization of the Escherichia coli gene for 1-acyl-sn-glycerol-3-phosphate acyltransferase (plsC). Mol. Gen. Genet. 232, 295\u2013303 (1992).","journal-title":"Mol. Gen. Genet."},{"key":"BFncomms12944_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/1471-2180-13-260","volume":"13","author":"JB Parsons","year":"2013","unstructured":"Parsons, J. B., Yao, J., Jackson, P., Frank, M. & Rock, C. O. Phosphatidylglycerol homeostasis in glycerol-phosphate auxotrophs of Staphylococcus aureus. BMC Microbiol. 13, 260 (2013).","journal-title":"BMC Microbiol."},{"key":"BFncomms12944_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1079\/BJN2002747","volume":"89","author":"T Nakamura","year":"2003","unstructured":"Nakamura, T. et al. Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study. Br. J. Nutr. 89, 267\u2013272 (2003).","journal-title":"Br. J. Nutr."},{"key":"BFncomms12944_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1365-2133.2011.10662.x","volume":"166","author":"S Ni Raghallaigh","year":"2012","unstructured":"Ni Raghallaigh, S., Bender, K., Lacey, N., Brennan, L. & Powell, F. C. The fatty acid profile of the skin surface lipid layer in papulopustular rosacea. Br. J. Dermatol. 166, 279\u2013287 (2012).","journal-title":"Br. J. Dermatol."},{"key":"BFncomms12944_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1099\/00221287-115-1-233","volume":"115","author":"DL Greenway","year":"1979","unstructured":"Greenway, D. L. & Dyke, K. G. Mechanism of the inhibitory action of linoleic acid on the growth of Staphylococcus aureus. J. Gen. Microbiol. 115, 233\u2013245 (1979).","journal-title":"J. Gen. Microbiol."},{"key":"BFncomms12944_CR38","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1128\/JB.00743-12","volume":"194","author":"JB Parsons","year":"2012","unstructured":"Parsons, J. B., Yao, J., Frank, M. W., Jackson, P. & Rock, C. O. Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus. J. Bacteriol. 194, 5294\u20135304 (2012).","journal-title":"J. Bacteriol."},{"key":"BFncomms12944_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1042\/BJ20130540","volume":"455","author":"C Schluepen","year":"2013","unstructured":"Schluepen, C. et al. Mining the bacterial unknown proteome: identification and characterization of a novel family of highly conserved protective antigens in Staphylococcus aureus. Biochem. J. 455, 273\u2013284 (2013).","journal-title":"Biochem. J."},{"key":"BFncomms12944_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/nar\/gkp909","volume":"38","author":"M Krishnamurthy","year":"2010","unstructured":"Krishnamurthy, M., Tadesse, S., Rothmaier, K. & Graumann, P. L. A novel SMC-like protein, SbcE (YhaN), is involved in DNA double-strand break repair and competence in Bacillus subtilis. Nucleic Acids Res. 38, 455\u2013466 (2010).","journal-title":"Nucleic Acids Res."},{"key":"BFncomms12944_CR41","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.febslet.2010.02.038","volume":"584","author":"SK Hong","year":"2010","unstructured":"Hong, S. K. et al. New design platform for malonyl-CoA-acyl carrier protein transacylase. FEBS Lett. 584, 1240\u20131244 (2010).","journal-title":"FEBS Lett."},{"key":"BFncomms12944_CR42","doi-asserted-by":"publisher","first-page":"12961","DOI":"10.1074\/jbc.270.22.12961","volume":"270","author":"L Serre","year":"1995","unstructured":"Serre, L., Verbree, E. C., Dauter, Z., Stuitje, A. R. & Derewenda, Z. S. The Escherichia coli malonyl-CoA:acyl carrier protein transacylase at 1.5-A resolution. Crystal structure of a fatty acid synthase component. J. Biol. Chem. 270, 12961\u201312964 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFncomms12944_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/mmi.12556","volume":"92","author":"JB Parsons","year":"2014","unstructured":"Parsons, J. B., Frank, M. W., Jackson, P., Subramanian, C. & Rock, C. O. Incorporation of extracellular fatty acids by a fatty acid kinase-dependent pathway in Staphylococcus aureus. Mol. Microbiol. 92, 234\u2013245 (2014).","journal-title":"Mol. Microbiol."},{"key":"BFncomms12944_CR44","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1128\/AAC.01741-15","volume":"60","author":"B Hafkin","year":"2015","unstructured":"Hafkin, B., Kaplan, N. & Murphy, B. Efficacy and safety of AFN-1252, the first staphylococcus-specific antibacterial agent, in the treatment of ABSSSI, including patients with significant co-morbidities. Antimicrob. Agents Chemother. 60, 1695\u20131701 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFncomms12944_CR45","doi-asserted-by":"publisher","first-page":"e63210","DOI":"10.1371\/journal.pone.0063210","volume":"8","author":"CJ Chen","year":"2013","unstructured":"Chen, C. J. et al. Characterization and comparison of 2 distinct epidemic community-associated methicillin-resistant Staphylococcus aureus clones of ST59 lineage. PLoS One 8, e63210 (2013).","journal-title":"PLoS One"},{"key":"BFncomms12944_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0076-6879(09)04617-5","volume":"459","author":"JE Cronan","year":"2009","unstructured":"Cronan, J. E. & Thomas, J. Bacterial fatty acid synthesis and its relationships with polyketide synthetic pathways. Methods Enzymol. 459, 395\u2013433 (2009).","journal-title":"Methods Enzymol."},{"key":"BFncomms12944_CR47","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nature12679","volume":"505","author":"A Masoudi","year":"2014","unstructured":"Masoudi, A., Raetz, C. R., Zhou, P. & Pemble, C. W. T. Chasing acyl carrier protein through a catalytic cycle of lipid A production. Nature 505, 422\u2013426 (2014).","journal-title":"Nature"},{"key":"BFncomms12944_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1179\/1973947812Y.0000000063","volume":"25","author":"N Kaplan","year":"2013","unstructured":"Kaplan, N. et al. In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. J. Chemother. 25, 18\u201325 (2013).","journal-title":"J. Chemother."},{"key":"BFncomms12944_CR49","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1128\/AAC.01562-06","volume":"51","author":"JH Yum","year":"2007","unstructured":"Yum, J. H. et al. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob. Agents Chemother. 51, 2591\u20132593 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFncomms12944_CR50","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1016\/S0021-9258(19)43197-9","volume":"248","author":"FE Ruch","year":"1973","unstructured":"Ruch, F. E. & Vagelos, P. R. The isolation and general properties of Escherichia coli malonyl coenzyme A-acyl carrier protein transacylase. J. Biol. Chem. 248, 8086\u20138094 (1973).","journal-title":"J. Biol. Chem."},{"key":"BFncomms12944_CR51","doi-asserted-by":"publisher","first-page":"e1003108","DOI":"10.1371\/journal.ppat.1003108","volume":"9","author":"D Albanesi","year":"2013","unstructured":"Albanesi, D. et al. Structural basis for feed-forward transcriptional regulation of membrane lipid homeostasis in Staphylococcus aureus. PLoS Pathog. 9, e1003108 (2013).","journal-title":"PLoS Pathog."},{"key":"BFncomms12944_CR52","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1534-5807(03)00123-0","volume":"4","author":"GE Schujman","year":"2003","unstructured":"Schujman, G. E., Paoletti, L., Grossman, A. D. & de Mendoza, D. FapR, a bacterial transcription factor involved in global regulation of membrane lipid biosynthesis. Dev. Cell 4, 663\u2013672 (2003).","journal-title":"Dev. Cell"},{"key":"BFncomms12944_CR53","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1021\/bi100136n","volume":"49","author":"MA Martinez","year":"2010","unstructured":"Martinez, M. A. et al. A novel role of malonyl-ACP in lipid homeostasis. Biochemistry 49, 3161\u20133167 (2010).","journal-title":"Biochemistry"},{"key":"BFncomms12944_CR54","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.4049\/jimmunol.181.6.4177","volume":"181","author":"TQ Do","year":"2008","unstructured":"Do, T. Q. et al. Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid. J. Immunol. 181, 4177\u20134187 (2008).","journal-title":"J. Immunol."},{"key":"BFncomms12944_CR55","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/jac\/dkw060","volume":"71","author":"YT Lin","year":"2016","unstructured":"Lin, Y. T. et al. Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin. J. Antimicrob. Chemother. 71, 1807\u20131814 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFncomms12944_CR56","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1099\/jmm.0.062752-0","volume":"62","author":"N Kubota","year":"2013","unstructured":"Kubota, N. et al. First isolation of oleate-dependent Enterococcus faecalis small-colony variants from the umbilical exudate of a paediatric patient with omphalitis. J. Med. Microbiol. 62, 1883\u20131890 (2013).","journal-title":"J. Med. Microbiol."},{"key":"BFncomms12944_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1126\/science.186.4158.19","volume":"186","author":"N Nicolaides","year":"1974","unstructured":"Nicolaides, N. Skin lipids: their biochemical uniqueness. Science 186, 19\u201326 (1974).","journal-title":"Science"},{"key":"BFncomms12944_CR58","doi-asserted-by":"publisher","first-page":"162S","DOI":"10.1177\/1091581810374127","volume":"29","author":"LC Becker","year":"2010","unstructured":"Becker, L. C. et al. Final report of the amended safety assessment of myristic acid and its salts and esters as used in cosmetics. Int. J. Toxicol. 29, 162S\u2013186S (2010).","journal-title":"Int. J. Toxicol."},{"key":"BFncomms12944_CR59","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.meegid.2013.04.020","volume":"21","author":"JR Fitzgerald","year":"2014","unstructured":"Fitzgerald, J. R. Evolution of Staphylococcus aureus during human colonization and infection. Infect. Genet. Evol. 21, 542\u2013547 (2014).","journal-title":"Infect. Genet. Evol."},{"key":"BFncomms12944_CR60","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1128\/IAI.00088-10","volume":"78","author":"S Herbert","year":"2010","unstructured":"Herbert, S. et al. Repair of global regulators in Staphylococcus aureus 8325 and comparative analysis with other clinical isolates. Infect. Immun. 78, 2877\u20132889 (2010).","journal-title":"Infect. Immun."},{"key":"BFncomms12944_CR61","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1126\/science.277.5331.1453","volume":"277","author":"FR Blattner","year":"1997","unstructured":"Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. Science 277, 1453\u20131462 (1997).","journal-title":"Science"},{"key":"BFncomms12944_CR62","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2958.2006.05406.x","volume":"62","author":"Y Yamamoto","year":"2006","unstructured":"Yamamoto, Y. et al. The Group B Streptococcus NADH oxidase Nox-2 is involved in fatty acid biosynthesis during aerobic growth and contributes to virulence. Mol. Microbiol. 62, 772\u2013785 (2006).","journal-title":"Mol. Microbiol."},{"key":"BFncomms12944_CR63","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nmeth.1318","volume":"6","author":"DG Gibson","year":"2009","unstructured":"Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343\u2013345 (2009).","journal-title":"Nat. Methods"},{"key":"BFncomms12944_CR64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mimet.2013.10.020","volume":"96","author":"MF Lartigue","year":"2014","unstructured":"Lartigue, M. F. & Bouloc, P. A tetracycline-inducible expression vector for Streptococcus agalactiae allowing controllable gene expression. J. Microbiol. Methods 96, 16\u201318 (2014).","journal-title":"J. Microbiol. Methods"},{"key":"BFncomms12944_CR65","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/BF02199440","volume":"21","author":"GR Kraemer","year":"1990","unstructured":"Kraemer, G. R. & Iandolo, J. J. High-frequency transformation of Staphylococcus aureus by electroporation. Curr. Microbiol. 21, 373\u2013376 (1990).","journal-title":"Curr. Microbiol."},{"key":"BFncomms12944_CR66","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0021-9258(18)52372-3","volume":"266","author":"D Post-Beittenmiller","year":"1991","unstructured":"Post-Beittenmiller, D., Jaworski, J. G. & Ohlrogge, J. B. In vivo pools of free and acylated acyl carrier proteins in spinach. Evidence for sites of regulation of fatty acid biosynthesis. J. Biol. Chem. 266, 1858\u20131865 (1991).","journal-title":"J. Biol. Chem."},{"key":"BFncomms12944_CR67","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrmicro1839","volume":"6","author":"YM Zhang","year":"2008","unstructured":"Zhang, Y. M. & Rock, C. O. Membrane lipid homeostasis in bacteria. Nat. Rev. Microbiol. 6, 222\u2013233 (2008).","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms12944.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms12944","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms12944.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T05:09:09Z","timestamp":1672808949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms12944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFncomms12944"],"URL":"https:\/\/doi.org\/10.1038\/ncomms12944","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726814440.793529627","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]},"assertion":[{"value":"27 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12944"}}